e-learning
resources
Munich 2006
Saturday 02.09.2006
PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Aetiology of CAP and HAP: role of microbiology
H. Goossens (Edegem, Belgium)
Source:
Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Session:
PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
Session type:
Postgraduate Course
Number:
47
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Goossens (Edegem, Belgium). Aetiology of CAP and HAP: role of microbiology. Annual Congress 2006 - PG1 - Respiratory infections: pneumonia/antibiotic resistance and clinical outcome of lower respiratory tract infections
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Management of severe community acquired pneumonia – ERS guidelines
Predictive indexes in prolonged weaning of mechanical ventilation due to tracheostomy in patients with COVID-19 pneumonia
Middle-long term pulmonary abnormalities after severe COVID-19 pneumonia which required invasive ventilation
Related content which might interest you:
Potential protective role of prior to diagnosis antibiotic treatment in community-acquired pneumonia: Clinical presentation and outcomes
Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections
Year: 2011
Severe community-acquired pneumonia in China: epidemiology and clinical practice
Source: International Congress 2019 – Chinese programme 2019: Part II
Year: 2019
Aetiology of CAP and HAP - role of noninvasive and invasive diagnostic methods
Source: Annual Congress 2003 - PG11 - Pneumonia epidemiology and diagnosis
Year: 2003
Community-acquired pneumonia (CAP) in the elderly : aetiology, role of aspiration and diagnostic procedures
Source: Eur Respir J 2002; 20: Suppl. 38, 420s
Year: 2002
Community-acquired pneumonia in outpatients: Microbial etiology
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010
Biomarkers and community-adquired pneumonia (CAP) etiology
Source: Annual Congress 2012 - Prognostic indices in respiratory infections
Year: 2012
Biomarkers and clinical stability in community-acquired pneumonia
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009
Etiology of community-acquired pneumonia: an autopsy study
Source: Annual Congress 2006 - Miscellaneous respiratory infections I
Year: 2006
Clinical pneumonia: how do I make a specific diagnosis?
Source: Virtual Congress 2021 – The "State of the Art" in the diagnosis of bacterial, mycobacterial, and fungal pneumonias
Year: 2021
Potential impact and relevance of diagnostics in the management of respiratory tract infections: from COVID to hospital-acquired pneumonia
Source: Virtual Congress 2021 – Emerging data for the management of respiratory tract infections
Year: 2021
The role of Chlamydia species as a cause of community-acquired pneumonia - clinical characteristics
Source: Eur Respir J 2005; 26: Suppl. 49, 409s
Year: 2005
Clinical factors associated with delayed diagnosis in hospitalized community-acquired pneumonia (CAP). Impact on the outcome
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010
Factors associated with unknown aetiology in patients with community-acquired pneumonia
Source: Eur Respir J 2002; 20: 1254-1262
Year: 2002
Relationship between etiologic diagnosis and prognosis in community-acquired pneumonia
Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants
Year: 2015
Severe community acquired pneumonia: clinical and aetiological evaluation
Source: Eur Respir J 2007; 30: Suppl. 51, 673s
Year: 2007
Biomarkers in community-acquired pneumonia: still searching for the one
Source: Eur Respir J, 53 (2) 1802469; 10.1183/13993003.02469-2018
Year: 2019
Atypical bacterial and viral ethiology of community-acquired pneumonia in Chile: a preliminary report
Source: Eur Respir J 2006; 28: Suppl. 50, 352s
Year: 2006
Viral vs bacterial community-acquired pneumonia: Radiologic features
Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections
Year: 2011
PES in CAP: An acronym to identify "problematic pathogens" in community-acquired pneumonia
Source: Annual Congress 2012 - Management of severe respiratory infections
Year: 2012
Biomarkers for the prognostic assessment and disease severity evaluation in community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept